McKesson Corporation Acquires Precision Medicine Group for $2.25 Billion to Expand Oncology Services
McKesson Corporation announced a $2.25 billion acquisition of Precision Medicine Group to expand its specialty services in oncology. The deal, which includes the Bethesda, Md.-based life sciences services platform, aims to deepen McKesson's footprint in the specialty healthcare market, specifically in oncology clinical trials and commercial services. Analysts at Morgan Stanley have responded favorably to the move, maintaining an Overweight rating and setting a target price near $977. While the acquisition strengthens McKesson's position as a top pharmaceutical wholesaler, GuruFocus data indicates the stock is currently trading at a modest premium of approximately 8.9% over its intrinsic value. Precision Medicine Group was a portfolio company of Blackstone Inc. The deal involved several legal and financial advisors, including Simpson Thacher & Bartlett LLP and Centerview Partners LLC. This acquisition follows a series of recent strategic moves by McKesson, including a stake sale to Apollo Global Management Inc. and the purchase of a controlling interest in Prism Vision Holdings LLC.